Neogen Corporation (NEOG)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Neogen Corporation.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Appears in These Scanners
This stock currently matches 7 of our scanner strategies — each hit links to the scanner.
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. View all scanners
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 12.00 $ — 100% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
3 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years 1.9% failed
- More than 10% revenue growth is expected for the coming year -1.0% failed
- Share count grows by less than 3% a year 4.8% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") 1.0% failed
- Gross margin at 40% or higher and without meaningful erosion 46.9% failed
- Goodwill from acquisitions does not grow faster than revenue 31.3% passed
- Net debt below twice EBITDA 186 m net cash passed
- Operating cash flow covers the profits of the last three years 1,286 m passed
- Return on capital at 15% or higher, or up versus two years ago -0.7% failed
- Insiders hold at least 10% or are net buyers 1.0% failed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Analysts & Price Target
The price target sits 8.3% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 3
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 05/31/2027 | 0.31 | 0.28 – 0.35 | 883 | -3.1% | 3 |
| 05/31/2028 | 0.38 | 0.32 – 0.43 | 866 | 22.6% | 3 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -2.10 | – | 231 | 0.70 | -197.30 | 40 | 23 |
| 2025: Q1 | -0.05 | – | 221 | -3.40 | -5.00 | 19 | -14 |
| 2025: Q2 | -2.82 | – | 226 | -4.80 | -271.50 | 17 | 0 |
| 2025: Q3 | 0.17 | – | 209 | -3.60 | 17.40 | 11 | -13 |
| 2025: Q4 | -0.07 | – | 225 | -2.80 | -7.10 | 19 | 43 |
| 2026: Q1 | -0.08 | – | 211 | -4.40 | -8.00 | 23 | 11 |
| 2026: Q2 | -0.06 | 97.90 | 225 | -0.10 | -5.00 | 30 | 30 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2017 | 362 | 65 | 44 | 0.43 | 60 | 472 | 528 |
| 2018 | 402 | 70 | 63 | 0.61 | 69 | 560 | 618 |
| 2019 | 414 | 68 | 60 | 0.57 | 64 | 638 | 696 |
| 2020 | 418 | 68 | 59 | 0.56 | 86 | 725 | 797 |
| 2021 | 468 | 74 | 61 | 0.57 | 81 | 840 | 920 |
| 2022 | 527 | 59 | 48 | 0.45 | 68 | 887 | 993 |
| 2023 | 822 | 38 | -23 | -0.12 | 41 | 3,134 | 4,554 |
| 2024 | 924 | 77 | -9 | -0.04 | 35 | 3,144 | 4,549 |
| 2025 | 895 | 9 | -1,092 | -5.03 | 58 | 2,071 | 3,444 |
| 2026 | 870 | -22 | -8 | -0.04 | 83 | 2,093 | 3,346 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Neogen Corporation entwickelt, fertigt und vermarktet verschiedene Produkte und Dienstleistungen für Lebensmittel- und Tiersicherheit in den USA und international. Sie ist in zwei Segmenten tätig: Food Safety und Animal Safety.
| Employees | 2,974 |
|---|---|
| Headquarters | Lansing, MI |
| Address | 620 Lesher Place, 48912-1595 Lansing, United States |
| Phone | 517 372 9200 |
| Website | neogen.com |
| IPO Date | 23. Aug 1989 |
| ISIN | US6404911066 |
| Stock Split | 2:1 on 06/07/2021 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Mikhael Nassif | CEO, President & Director | – |
| R. Bryan Riggsbee CPA | CFO & Senior Vice President | 1970 |
| John Moylan | VP, Corporate Controller & Chief Accounting Officer | – |
| Jeremy Yarwood | Chief Scientific Officer | – |
| Sarah Demey | Administrative Manager | – |
| Bill Waelke | Head of Investor Relations | – |
| Jennifer Evans Stacey Esq., J.D. | Chief Legal & Compliance Officer and Board Secretary | 1965 |
| Kevin M. Burke | Chief Human Resources Officer | 1969 |
| Joe Freels | Senior VP & Chief Commercial Officer | – |
| Tamara A. Ranalli Ph.D. | Senior VP & GM of Global Food Safety | 1974 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.